Cargando…

A Comparison of the Current N2 Classification and a Modified N2 Categorization in TNM Staging of Esophageal Cancer Patients

OBJECTIVE: To compare the effectiveness of the current N classification and a modified N2 categorization in TNM staging of esophageal cancer (EC) patients. METHODOLOGY: A total of 2753 EC patients were enrolled in the study: 2283 EC patients from the Surveillance, Epidemiology, and End Results (SEER...

Descripción completa

Detalles Bibliográficos
Autores principales: Xi, Kexing, Yu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856417/
https://www.ncbi.nlm.nih.gov/pubmed/33552951
http://dx.doi.org/10.3389/fonc.2020.561363
_version_ 1783646245152096256
author Xi, Kexing
Yu, Hui
author_facet Xi, Kexing
Yu, Hui
author_sort Xi, Kexing
collection PubMed
description OBJECTIVE: To compare the effectiveness of the current N classification and a modified N2 categorization in TNM staging of esophageal cancer (EC) patients. METHODOLOGY: A total of 2753 EC patients were enrolled in the study: 2283 EC patients from the Surveillance, Epidemiology, and End Results (SEER) database and 470 separate Chinese patients were used to verify the results of the SEER database. X-tile software was employed to determine the optimal cutoff points of the number of metastatic lymph nodes (LNs) in the N2 category. Univariate and multivariate Cox regression analyses were performed to identify the survival risk factors. RESULT: Patients in the N2 category were divided into two groups based on the number of metastatic LNs. Patients with three and four metastatic LNs were categorized as N2a, while those with five and six metastatic LNs were categorized as N2b. The 3-year overall survival (OS) rate in the SEER database was 71.5%, 42.3%, 23.6%, 17.2%, and 10.7% for patients with N0, N1, N2a, N2b, and N3, respectively (P<0.001). Furthermore, a separate Chinese cohort was enrolled to validate the revised N2 category. Additionally, the 3-year OS rate was 71.5%, 42.3%, 23.6%, 17.2%, and 10.7% for patients with N0, N1, N2a, N2b, and N3, respectively (P<0.001). CONCLUSION: The current N2 category should be further divided into two groups (N2a and N2b) to provide more accurate prognosis information that could further help in developing personalized therapeutic strategies.
format Online
Article
Text
id pubmed-7856417
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78564172021-02-04 A Comparison of the Current N2 Classification and a Modified N2 Categorization in TNM Staging of Esophageal Cancer Patients Xi, Kexing Yu, Hui Front Oncol Oncology OBJECTIVE: To compare the effectiveness of the current N classification and a modified N2 categorization in TNM staging of esophageal cancer (EC) patients. METHODOLOGY: A total of 2753 EC patients were enrolled in the study: 2283 EC patients from the Surveillance, Epidemiology, and End Results (SEER) database and 470 separate Chinese patients were used to verify the results of the SEER database. X-tile software was employed to determine the optimal cutoff points of the number of metastatic lymph nodes (LNs) in the N2 category. Univariate and multivariate Cox regression analyses were performed to identify the survival risk factors. RESULT: Patients in the N2 category were divided into two groups based on the number of metastatic LNs. Patients with three and four metastatic LNs were categorized as N2a, while those with five and six metastatic LNs were categorized as N2b. The 3-year overall survival (OS) rate in the SEER database was 71.5%, 42.3%, 23.6%, 17.2%, and 10.7% for patients with N0, N1, N2a, N2b, and N3, respectively (P<0.001). Furthermore, a separate Chinese cohort was enrolled to validate the revised N2 category. Additionally, the 3-year OS rate was 71.5%, 42.3%, 23.6%, 17.2%, and 10.7% for patients with N0, N1, N2a, N2b, and N3, respectively (P<0.001). CONCLUSION: The current N2 category should be further divided into two groups (N2a and N2b) to provide more accurate prognosis information that could further help in developing personalized therapeutic strategies. Frontiers Media S.A. 2021-01-19 /pmc/articles/PMC7856417/ /pubmed/33552951 http://dx.doi.org/10.3389/fonc.2020.561363 Text en Copyright © 2021 Xi and Yu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xi, Kexing
Yu, Hui
A Comparison of the Current N2 Classification and a Modified N2 Categorization in TNM Staging of Esophageal Cancer Patients
title A Comparison of the Current N2 Classification and a Modified N2 Categorization in TNM Staging of Esophageal Cancer Patients
title_full A Comparison of the Current N2 Classification and a Modified N2 Categorization in TNM Staging of Esophageal Cancer Patients
title_fullStr A Comparison of the Current N2 Classification and a Modified N2 Categorization in TNM Staging of Esophageal Cancer Patients
title_full_unstemmed A Comparison of the Current N2 Classification and a Modified N2 Categorization in TNM Staging of Esophageal Cancer Patients
title_short A Comparison of the Current N2 Classification and a Modified N2 Categorization in TNM Staging of Esophageal Cancer Patients
title_sort comparison of the current n2 classification and a modified n2 categorization in tnm staging of esophageal cancer patients
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856417/
https://www.ncbi.nlm.nih.gov/pubmed/33552951
http://dx.doi.org/10.3389/fonc.2020.561363
work_keys_str_mv AT xikexing acomparisonofthecurrentn2classificationandamodifiedn2categorizationintnmstagingofesophagealcancerpatients
AT yuhui acomparisonofthecurrentn2classificationandamodifiedn2categorizationintnmstagingofesophagealcancerpatients
AT xikexing comparisonofthecurrentn2classificationandamodifiedn2categorizationintnmstagingofesophagealcancerpatients
AT yuhui comparisonofthecurrentn2classificationandamodifiedn2categorizationintnmstagingofesophagealcancerpatients